Skip to main content
. 2021 Dec 17;13(1):6. doi: 10.1038/s41419-021-04447-4

Fig. 1. RPRD1A was overexpressed in HCC samples, and its overexpression correlated with aggressive clinicopathological features.

Fig. 1

A Real-time PCR (RT-PCR) analysis of RPRD1A mRNA expression in 24 paired primary tumor (T), para-tumor (P), and normal tissues (N) obtained from the Eastern Hepatobiliary Surgery Hospital (EHBH). B Western blotting analysis of RPRD1A protein expression in 9 paired HCC tumor, para-tumor, and normal tissues obtained from the EHBH. C Representative images of RPRD1A staining (score 0, 1, 2, 3) in HCC tissue microarray and the case distribution of different staining scores were shown. D, E (D) Overall survival (OS) and (E) disease-free survival (DFS) in an HCC cohort obtained from EHBH according to the RPRD1A expression, the log-rank test was used to determine significance. F RPRD1A expression in 50 paired HCC tumor and normal tissues from the TCGA database. G RPRD1A expression in 374 cases of HCC and 50 cases of normal tissues from the TCGA database. H Overall survival time in an HCC cohort with 343 cases obtained from the TCGA database according to the RPRD1A mRNA expression. I Expression of RPRD1A in tumor T1&T2 and T3&T4 in the database. J–K (J) RT-PCR and (K) western blotting analysis of RPRD1A in normal liver (N), para-tumor (P), primary tumor (T), and portal vein tumor thrombosis tissues (PVTT). L IHC staining and statistical analysis of the RPRD1A expression (score 0, 1, 2, 3) in PVTT, HCC, and para-tumor tissues. Scale bars, 200 μm. In panels D, E, H, p values were determined by the log-rank test. In panels F, G, I, the p values were determined by a two-tailed t-test. *p < 0.05, **p < 0.01, ***p < 0.001.